Tegavivint for Colorectal Cancer

This trial explores the effectiveness of a new treatment, tegavivint, for individuals with metastatic colorectal cancer that has spread and no longer responds to standard treatments. The primary goal is to assess the safety and initial effectiveness of tegavivint alone and in combination with other common cancer therapies. It is suitable for those with advanced colorectal cancer that has not improved after at least two different treatments. Participants must provide samples for testing during the trial. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial requires a washout period (time without taking certain medications) of at least 21 days from the last dose of prior systemic anticancer treatment. Additionally, you must stop taking any strong or moderate inhibitors or inducers of CYP3A4/5 before starting the trial. Please discuss with your doctor to understand how this applies to your specific medications.

Previous studies have shown that tegavivint is well-tolerated by patients, with mostly mild side effects. Research indicates that when used alone, most side effects are mild and not serious. In another study involving patients with advanced liver cancer, 62.5% experienced mild treatment-related side effects, and no severe side effects were reported. These findings suggest that tegavivint is generally safe for use in humans, with manageable side effects.¹²³⁴⁵

Tegavivint is unique because it targets the TBL1 protein, a novel approach in treating colorectal cancer. Unlike standard treatments like chemotherapy and targeted therapies, which often focus on inhibiting cancer cell growth directly, Tegavivint interferes with the cancer cell's signaling pathways, potentially stopping cancer growth more effectively. This distinct mechanism offers hope for improved outcomes, especially for patients who have limited responses to existing therapies. Researchers are excited about Tegavivint's potential to provide a new treatment pathway and its capability to be combined with existing standard care, potentially enhancing overall treatment efficacy.

Research suggests that tegavivint, a new medication, shows promise for treating colorectal cancer. In this trial, some participants will receive tegavivint as a monotherapy. Studies have shown that it can slow tumor growth and boost the immune system in certain types of colorectal cancer. Early clinical data indicate that it is generally well-tolerated, and some patients have responded well when used alone. Other participants will receive tegavivint combined with standard treatments. In studies, this combination showed a 27.6% overall response rate in a small group of patients, with some experiencing partial tumor shrinkage. These findings suggest that tegavivint may effectively treat advanced colorectal cancer.¹²³⁴⁶